Exploration of differentially expressed plasma proteins in patients with lung adenocarcinoma using iTRAQ-coupled 2D LC-MS/MS.

Plasma SCGB3A2 is a potential maker for diagnosis of primary pulmonary adenocarcinoma. Abnormal post-translational protein modification may be associated with the progression of lung cancer.